

Simon R Lord

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1411537/publications.pdf>

Version: 2024-02-01

26
papers

1,332
citations

759233

12
h-index

677142

22
g-index

26
all docs

26
docs citations

26
times ranked

2208
citing authors

#	ARTICLE	IF	CITATIONS
1	The current status of risk-stratified breast screening. <i>British Journal of Cancer</i> , 2022, 126, 533-550.	6.4	47
2	Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging. <i>British Journal of Cancer</i> , 2022, 126, 598-605.	6.4	4
3	Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications. <i>Seminars in Cancer Biology</i> , 2022, 86, 851-859.	9.6	39
4	Abstract PD10-03: BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): Results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O). <i>Cancer Research</i> , 2022, 82, PD10-03-PD10-03.	0.9	2
5	CGE22-097: Mapping the Mutational Landscape in Patients With Advanced Malignancies Enrolled to Early Phase Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, CGE22-097.	4.9	0
6	VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface. <i>Clinical Cancer Research</i> , 2022, 28, 2385-2396.	7.0	7
7	Development and validation of clinical prediction models for breast cancer incidence and mortality: a protocol for a dual cohort study. <i>BMJ Open</i> , 2022, 12, e050828.	1.9	4
8	Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 45.	5.2	16
9	Abstract 1247: Comprehensive molecular profiling to predict first-line immunochemotherapy outcomes in inoperable esophageal adenocarcinoma. <i>Cancer Research</i> , 2022, 82, 1247-1247.	0.9	0
10	Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits. <i>Journal of Medical Genetics</i> , 2021, 58, 392-399.	3.2	9
11	Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 125, 520-527.	6.4	37
12	BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC) – Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1023-1023.	1.6	49
13	Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer. <i>The Cochrane Library</i> , 2021, 2021, .	2.8	0
14	Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. <i>British Journal of Cancer</i> , 2020, 122, 258-265.	6.4	28
15	Window of opportunity clinical trial designs to study cancer metabolism. <i>British Journal of Cancer</i> , 2020, 122, 45-51.	6.4	14
16	Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2019, 20, 1124-1135.	10.7	339
17	Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 12452-12461.	7.1	86
18	Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 137-153.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. <i>Cell Metabolism</i> , 2018, 28, 679-688.e4.	16.2	92
20	Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. <i>EBioMedicine</i> , 2016, 10, 109-116.	6.1	27
21	Early phase cancer clinical trials: design, ethics and future directions. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2015, 76, 409-413.	0.5	2
22	Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 81-86.	2.1	8
23	Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?. <i>Cancer Investigation</i> , 2015, 33, 347-353.	1.3	1
24	Fatty Acid Uptake and Lipid Storage Induced by HIF-1 α Contribute to Cell Growth and Survival after Hypoxia-Reoxygenation. <i>Cell Reports</i> , 2014, 9, 349-365.	6.4	498
25	Angiogenesis - still a worthwhile target for breast cancer therapy?. <i>Breast Cancer Research</i> , 2010, 12, S19.	5.0	11
26	Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 172-199.	0.8	6